<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35314925</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1434-9949</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical rheumatology</Title>
          <ISOAbbreviation>Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-022-06130-1</ELocationID>
        <Abstract>
          <AbstractText>There have been hundreds of reports on mutations in the NLRP3 gene related to NLRP3-associated autoinflammatory disease, but few of these mutations have occurred as both germline and somatic mosaic mutations. In this case-based review, we report a 68-year-old man with an NLRP3-associated autoinflammatory disease. He developed secondary amyloidosis, including a renal and colorectal presentation in his 50 s. Sequencing of the NLRP3 gene revealed an I574F somatic mosaic mutation, which has up to now only been reported in germline mutations. The patient was treated with canakinumab, which had great efficacy not only on the NLRP3-mediated inflammation, but also on the chronic renal failure and proteinuria provoked by secondary renal amyloidosis. To evaluate the effectiveness of canakinumab, we conducted a literature research on renal amyloidosis related to NLRP3-associated autoinflammatory disease treated with canakinumab. Although our patient had a relatively long medical history and greater amounts of proteinuria than other reported cases, canakinumab had great efficacy on renal impairment, in similar to other reported cases. Along with the first report of a late-onset I574F somatic mosaic mutation in NLRP3-associated autoinflammatory disease, this report demonstrates the effectiveness of canakinumab on renal amyloidosis, probably through the way that IL-1β blockade minimizes podocyte injury.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Itamiya</LastName>
            <ForeName>Takahiro</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-1020-0108</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Komai</LastName>
            <ForeName>Toshihiko</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-5890-3606</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. KOMAIT-INT@h.u-tokyo.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanda</LastName>
            <ForeName>Hiroko</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-0968-0183</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Immune-Mediated Diseases Therapy Center, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nagafuchi</LastName>
            <ForeName>Yasuo</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-1316-8035</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Hyangri</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genomic Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shibata</LastName>
            <ForeName>Shota</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-9131-5408</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishiura</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-2975-7309</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Genomic Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shoda</LastName>
            <ForeName>Hirofumi</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-1536-0303</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toda</LastName>
            <ForeName>Tatsushi</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-0717-1123</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Genomic Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujio</LastName>
            <ForeName>Keishi</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0001-7276-5254</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Clin Rheumatol</MedlineTA>
        <NlmUniqueID>8211469</NlmUniqueID>
        <ISSNLinking>0770-3198</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Clin Rheumatol. 2022 Apr 1;:</RefSource>
          <PMID Version="1">35362833</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Canakinumab</Keyword>
        <Keyword MajorTopicYN="N">Muckle-Wells syndrome</Keyword>
        <Keyword MajorTopicYN="N">NLRP3-associated autoinflammatory disease</Keyword>
        <Keyword MajorTopicYN="N">Renal amyloidosis</Keyword>
        <Keyword MajorTopicYN="N">Somatic mosaic mutation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35314925</ArticleId>
        <ArticleId IdType="doi">10.1007/s10067-022-06130-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s10067-022-06130-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ben-Chetrit E, Gattorno M, Gul A et al (2018) Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis 77:1558–1565. https://doi.org/10.1136/annrheumdis-2017-212515</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-212515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lepore L, Paloni G, Caorsi R et al (2010) Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra. J Pediatr 157:310-315.e311. https://doi.org/10.1016/j.jpeds.2010.02.040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2010.02.040</ArticleId>
            <ArticleId IdType="pubmed">20472245</ArticleId>
            <ArticleId IdType="pmc">20472245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka N, Izawa K, Saito MK et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an international multicenter collaborative study. Arthritis Rheum 63:3625–3632. https://doi.org/10.1002/art.30512</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.30512</ArticleId>
            <ArticleId IdType="pubmed">3498501</ArticleId>
            <ArticleId IdType="pmc">3498501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Louvrier C, Assrawi E, El Khouri E et al (2019) NLRP3-associated autoinflammatory diseases: phenotypic and molecular characteristics of germline versus somatic mutations. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2019.11.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2019.11.035</ArticleId>
            <ArticleId IdType="pubmed">31816408</ArticleId>
            <ArticleId IdType="pmc">31816408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papa R, Doglio M, Lachmann HJ et al (2017) A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet J Rare Dis 12:167. https://doi.org/10.1186/s13023-017-0720-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-017-0720-3</ArticleId>
            <ArticleId IdType="pubmed">5648458</ArticleId>
            <ArticleId IdType="pmc">5648458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eroglu FK, Kasapcopur O, Beşbaş N et al (2016) Genetic and clinical features of cryopyrin-associated periodic syndromes in Turkish children. Clin Exp Rheumatol 34:S115-s120</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27191192</ArticleId>
            <ArticleId IdType="pmc">27191192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolaños L, Mosquera-Reboredo JM, Cao M et al (2013) Renal and thyroid amyloidosis secondary tocryopyrin-associated periodic syndrome(Muckle-Wells syndrome) (NLRP3 mutation). Nefrologia 33:266–271. https://doi.org/10.3265/Nefrologia.pre2012.Oct.11775</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3265/Nefrologia.pre2012.Oct.11775</ArticleId>
            <ArticleId IdType="pubmed">23511763</ArticleId>
            <ArticleId IdType="pmc">23511763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarpioni R, Rigante D, Cantarini L et al (2015) Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1beta monoclonal antibody canakinumab. Clin Rheumatol 34:1311–1316. https://doi.org/10.1007/s10067-013-2481-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-013-2481-2</ArticleId>
            <ArticleId IdType="pubmed">24510061</ArticleId>
            <ArticleId IdType="pmc">24510061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topaloglu R, Batu ED, Orhan D et al (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31:633–640. https://doi.org/10.1007/s00467-015-3249-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00467-015-3249-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>İlgen U, KÜÇÜkŞahİn O (2020) Additional benefit of canakinumab on proteinuria in a case with Muckle-Wells syndrome in remission under anakinra. Arch Rheumatol 35:149–150. https://doi.org/10.5606/ArchRheumatol.2020.7378</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5606/ArchRheumatol.2020.7378</ArticleId>
            <ArticleId IdType="pubmed">32637933</ArticleId>
            <ArticleId IdType="pmc">32637933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210–215. https://doi.org/10.1038/nri2725</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westermark GT, Fändrich M, Westermark P (2015) AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10:321–344. https://doi.org/10.1146/annurev-pathol-020712-163913</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pathol-020712-163913</ArticleId>
            <ArticleId IdType="pubmed">25387054</ArticleId>
            <ArticleId IdType="pmc">25387054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuvolone M, Merlini G (2017) Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant 32:770–780. https://doi.org/10.1093/ndt/gfw305</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfw305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varan O, Kucuk H, Babaoglu H et al (2019) Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 29:363–366. https://doi.org/10.1080/14397595.2018.1457469</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14397595.2018.1457469</ArticleId>
            <ArticleId IdType="pubmed">29578360</ArticleId>
            <ArticleId IdType="pmc">29578360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akar S, Cetin P, Kalyoncu U et al (2018) Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients. Arthritis Care Res (Hoboken) 70:1090–1094. https://doi.org/10.1002/acr.23446</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.23446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ugurlu S, Ergezen B, Egeli BH et al (2020) Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 59:3892–3899. https://doi.org/10.1093/rheumatology/keaa211</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keaa211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al (2011) Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 63:840–849. https://doi.org/10.1002/art.30149</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.30149</ArticleId>
            <ArticleId IdType="pubmed">21360513</ArticleId>
            <ArticleId IdType="pmc">21360513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong W, Meng XF, Zhang C (2020) Inflammasome activation in podocytes: a new mechanism of glomerular diseases. Inflamm Res 69:731–743. https://doi.org/10.1007/s00011-020-01354-w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-020-01354-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachmann HJ, Goodman HJ, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371. https://doi.org/10.1056/NEJMoa070265</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa070265</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
